Actively Recruiting
MRI Screening for Brain Metastases Among Patients With Triple Negative or HER2+ Stage II or III Breast Cancer
Led by Sunnybrook Health Sciences Centre · Updated on 2025-12-18
100
Participants Needed
1
Research Sites
235 weeks
Total Duration
On this page
Sponsors
S
Sunnybrook Health Sciences Centre
Lead Sponsor
P
Princess Margaret Hospital, Canada
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this multi-centre, prospective study is to assess the frequency of asymptomatic brain metastasis in patients with stage IIb or III Triple Negative or HER2 positive breast cancer. The main questions it aims to answer are: 1. What proportion of patients with stage IIb or III Triple Negative or HER2 positive breast cancer have asymptomatic brain metastases identified on a screening contrast-enhanced magnetic resonance imaging (MRI) of the brain? 2. How do patients feel about undergoing brain imaging to screen for asymptomatic brain metastasis? 3. What clinical as well as liquid and tissue-based biomarkers are associated with asymptomatic detection of brain metastasis? Participants will undergo brain imaging, provide one blood sample (for analysis of ctDNA), and complete the Testing Morbidities Index (TMI) questionnaire after imaging is done. Procedures may take place either prior to or after completion of (neo)-adjuvant systemic therapy; however, the study interventions must take place within 18 months of initial breast cancer diagnosis.
CONDITIONS
Official Title
MRI Screening for Brain Metastases Among Patients With Triple Negative or HER2+ Stage II or III Breast Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age over 18 years
- Diagnosis of Triple Negative or HER2 positive breast cancer according to 2018 ASCO/CAP guidelines
- Stage IIb or III breast cancer
- Patients with previous or other cancers that do not interfere with study safety or results may participate
- Ability and willingness to provide informed consent
You will not qualify if you...
- Creatinine clearance less than 30 mL/min as measured by the Cockcroft-Gault equation
- Pregnant women are not allowed to participate due to unknown safety of IV contrast
- Patients with central nervous system symptoms suggesting brain metastases needing brain imaging
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Sunnybrook Health Science Centre
Toronto, Ontario, Canada, M4N 3M5
Actively Recruiting
Research Team
K
Katarzyna Jerzak, MD, M.Sc
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
SCREENING
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here